Avestar Capital, LLC Vertex Pharmaceuticals Inc Transaction History

Avestar Capital, LLC

$951 Million
Q3 2024

A detailed history of Avestar Capital, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Avestar Capital, LLC holds 3,156 shares of VRTX stock, worth $1.42 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares

3,156

Previous 3,052 3.41%

Holding current value

$1.42 Million

Previous $1.43 Million 2.59%

% of portfolio

0.15%

Previous 0.15%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$460.0 - $505.78 $47,840 - $52,601	104 Added 3.41%	3,156 $1.47 Million
Q2 2024 Aug 08, 2024	BUY	$392.81 - $485.53 $58,135 - $71,858	148 Added 5.1%	3,052 $1.43 Million
Q1 2024 May 10, 2024	BUY	$407.69 - $446.08 $282,936 - $309,579	694 Added 31.4%	2,904 $1.21 Million
Q4 2023 Feb 12, 2024	BUY	$343.0 - $410.68 $81,291 - $97,331	237 Added 12.01%	2,210 $899,000
Q3 2023 Oct 20, 2023	BUY	$338.18 - $362.46 $7,778 - $8,336	23 Added 1.18%	1,973 $686,000
Q2 2023 Aug 01, 2023	SELL	$314.42 - $351.91 $314 - $351	-1 Reduced 0.05%	1,950 $686,000
Q1 2023 Apr 20, 2023	BUY	$283.23 - $323.1 $178,151 - $203,229	629 Added 47.58%	1,951 $614,000
Q4 2022 Jan 20, 2023	SELL	$285.76 - $321.48 $18,002 - $20,253	-63 Reduced 4.55%	1,322 $0
Q3 2022 Oct 26, 2022	SELL	$273.83 - $305.53 $87,351 - $97,464	-319 Reduced 18.72%	1,385 $401,000
Q2 2022 Jul 28, 2022	SELL	$234.96 - $292.55 $1.11 Million - $1.38 Million	-4,711 Reduced 73.44%	1,704 $480,000
Q1 2022 Apr 26, 2022	BUY	$221.42 - $260.97 $1.08 Million - $1.28 Million	4,886 Added 319.56%	6,415 $1.67 Million
Q4 2021 Feb 01, 2022	SELL	$177.01 - $223.45 $17,346 - $21,898	-98 Reduced 6.02%	1,529 $336,000
Q3 2021 Nov 09, 2021	BUY	$181.39 - $202.99 $23,217 - $25,982	128 Added 8.54%	1,627 $295,000
Q2 2021 Aug 03, 2021	BUY	$187.49 - $221.1 $38,810 - $45,767	207 Added 16.02%	1,499 $302,000
Q1 2021 May 03, 2021	BUY	$207.02 - $241.31 $19,045 - $22,200	92 Added 7.67%	1,292 $276,000
Q4 2020 Feb 01, 2021	BUY	$207.01 - $276.09 $38,710 - $51,628	187 Added 18.46%	1,200 $284,000
Q3 2020 Oct 29, 2020	BUY	$255.65 - $303.1 $56,243 - $66,682	220 Added 27.74%	1,013 $210,000
Q2 2020 Jul 29, 2020	BUY	$225.48 - $295.8 $178,805 - $234,569	793 New	793 $230,000
Q3 2019 Nov 14, 2019	SELL	$166.23 - $187.09 $112,039 - $126,098	-674 Closed	0 $0
Q2 2019 Aug 06, 2019	BUY	$164.61 - $190.37 $18,765 - $21,702	114 Added 20.36%	674 $107,000
Q1 2019 May 09, 2019	SELL	$163.73 - $194.7 $8,186 - $9,735	-50 Reduced 8.2%	560 $86,000
Q4 2018 Jan 25, 2019	SELL	$151.91 - $192.21 $8,355 - $10,571	-55 Reduced 8.27%	610 $75,000
Q3 2018 Oct 23, 2018	BUY	$167.73 - $192.74 $6,373 - $7,324	38 Added 6.06%	665 $107,000
Q2 2018 Aug 10, 2018	BUY	$145.72 - $169.96 $22,295 - $26,003	153 Added 32.28%	627 $91,000
Q1 2018 May 10, 2018	BUY	$151.6 - $177.13 $9,550 - $11,159	63 Added 15.33%	474 $57,000
Q4 2017 Feb 14, 2018	BUY	$137.28 - $155.55 $56,422 - $63,931	411	411 $45,000

Others Institutions Holding VRTX

# of Institutions

1,723

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Avestar Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Avestar Capital, LLC with notifications on news.

Account

Avestar Capital, LLC Vertex Pharmaceuticals Inc Transaction History